Corporate Profile

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Recent News

  • Nov 12, 2018

    GAITHERSBURG, Md. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced several management promotions. “We are pleased to announce several key management promotions to further support the advancement of our company and its lead clinical programs into commercial stage,"...More>>

  • Nov 07, 2018

    Company to Host Conference Call Today at 4:30 p.m. ET GAITHERSBURG, Md. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter and nine months ended September 30, 2018 ....More>>

  • Nov 01, 2018

    GAITHERSBURG, Md. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its third quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, November 7, 2018 . Conference call details are as follows: Date: ...More>>

Stock Quote